Dexmedetomidine HCl - Moligand™,10mM in DMSO , Adrenergic receptor alpha-2 agonist, CAS No.145108-58-3, Adrenergic receptor alpha-2 agonist

CAS: 145108-58-3 Cat. No.: D409289 Peso molecular: 236.74 Número EC: 682-047-2

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

5-​[(1S)​-​1-​(2,​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole,hydrochloride (1:1)

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Descripción general

Information

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.
In vitro

In vivo

Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥99%

Specifications

Sinónimos

5-​[(1S)​-​1-​(2, ​3-​dimethylphenyl)​ethyl]​-​1H-​imidazole, hydrochloride (1:1)

Especificaciones y pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos y fisiológicos

Dexmedetomidine HCl is a highly selective and potent alpha-2 adrenoceptor agonist, which reduces anesthetic requirements for patients by providing significant sedation.

Condiciones de almacenamiento de almacenamiento

Store at -80°C

Enviado en

Dry ice packs + Cold packs

Este producto requiere envío en cadena de frío. Los servicios terrestres y otros servicios económicos no están disponibles.

Grado

Moligand™

Tipo de acción

AGONIST

Mecanismo de acción

Adrenergic receptor alpha-2 agonist

Nombres e identificadores

• Isómeros SMILES: CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C.Cl
• WGK Alemania: 3
• RTECS: NI5156750
• Peso molecular: 236.74
• Reaxy-Rn: 5362300
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=5362300&ln=

Propiedades químicas y físicas

• Solubilidad: Solubility (25°C) In vitro Water: 34 mg/mL (198.65 mM); DMSO: 7 mg/mL (40.89 mM); Ethanol: Insoluble
• Rotación específica [α]: 51° (C=1,H2O)
• Punto de fusión (°C): 158 °C

Referencias

1. Kaiyu Xu, Ying Zhang, Yongxuan Chen, Xiaojia Zhu, Yu Li, Longbao Lv, Xiechao He, Zhengfei Hu, Yifan Li, Maosen Ye, Dewei Jiang, Zhanlong He, Weihua Jin, Yanyan Li, Xiaomei Yu, Deng-Feng Zhang, Karl Herrup, Ping Zheng, Yong-Gang Yao, Dong-Dong Wu, Jiali Li.  (2025)  ATM deficiency drives phenotypic diversity and Purkinje cell degeneration in a macaque model of ataxia-telangiectasia.  Cell Reports Medicine,      [PMID:40961921] [10.1016/j.xcrm.2025.102355]

2. Qiuxia Liao, Zhi Feng, Hairong Lin, Ye Zhou, Xinxin Lin, Xiao Lin, Huichang Zhuo.  (2025)  Dexmedetomidine improves septic acute kidney injury by inhibiting inflammation and oxidative stress through the activation of the Pink1/Park2 autophagy pathway.  RENAL FAILURE,      [PMID:40485166] [10.1080/0886022X.2025.2513677]

3. Ce Wu, Di Wu, LiJie Xie, HouYong Yan, Wei Zhang, Fei Yu.  (2026)  Near-Infrared Responsive Injectable Thermosensitive Hydrogel Sequentially Releases Dexmedetomidine and Ropivacaine for Postoperative Pain Management.  COLLOIDS AND SURFACES A-PHYSICOCHEMICAL AND ENGINEERING ASPECTS,      [PMID:] [10.1016/j.colsurfa.2026.139503]